CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Panitumumab +2 morebiological
Likely dose
Panitumumab 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00891930
NCT00891930Phase 2Completed
CompareCT.gov

Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin-or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab

NantBioScience, Inc.·interventional·Posted May 1, 2009·Updated Jul 17, 2024

In Brief

A Phase 2 clinical trial evaluating Panitumumab, Ganitumab, and 1 other intervention for Metastatic Colorectal Cancer. Completed, enrolled 74 participants.

Detailed Summary

This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in metastatic colorectal carcinoma (mCRC) patients with wild-type Kirsten rat sarcoma-2 virus oncogene (KRAS) tumor status at the time of initial diagnosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 1, 2009
Enrollment StartMay 5, 2009
Primary CompletionJul 22, 2013
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.2 years ago

Interventions

Panitumumabbiological

Panitumumab 6 mg/kg administered via IV infusion over 60 minutes

Ganitumabbiological

AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes

Irinotecandrug

Irinotecan starting dose of 180 mg/m² adminstered via IV infusion